Abstract
This protocol describes a planned systematic review and meta-analysis to evaluate the clinical efficacy of Shexiang Baoxin Pill (SBP) in combination with statins for patients with coronary heart disease (CHD). The primary objective is to assess improvements in blood lipid profiles and clinical symptoms compared to statin monotherapy. By synthesizing data from randomized controlled trials (RCTs), this study aims to provide evidence-based recommendations for integrated cardiovascular care.
Introduction
Coronary Heart Disease (CHD) remains a leading cause of global mortality, with dyslipidemia serving as a critical modifiable risk factor. While statin therapy is the established standard of care for lipid management, adjunctive therapies are frequently sought to enhance clinical outcomes. In China, the Shexiang Baoxin Pill (SBP)—a traditional Chinese patent medicine derived from an ancient Song Dynasty formula—is widely used alongside statins.
Preclinical evidence suggests that SBP exerts pleiotropic effects, potentially improving lipid metabolism and offering cardiovascular protection through multiple biological pathways. However, a rigorous, quantitative synthesis of its clinical efficacy in combination with statins is currently lacking. This systematic review protocol addresses the need for a high-level evaluation to inform clinicians about the risks, benefits, and optimal dosages of this combination therapy.
Methodology
The review will be conducted in accordance with the Preferred Reporting Items for Systematic Review and Meta-Analysis Protocols (PRISMA-P) guidelines.
Study Selection and Eligibility
The analysis will exclusively include Randomized Controlled Trials (RCTs). Participants must be diagnosed with CHD according to established international or national standards, such as those from the World Health Organization (WHO) or the International Society of Cardiology and Association (ISCA). Trials must compare the combination of statins and SBP against statin monotherapy.
Intervention and Comparison
The study follows the PICO framework:
- Population (P): Patients diagnosed with coronary heart disease.
- Intervention (I): Combination therapy of statins and Shexiang Baoxin Pill.
- Comparison (C): Statin monotherapy.
- Outcomes (O): Primary outcomes include changes in blood lipid markers (LDL-C, HDL-C, Total Cholesterol, and Triglycerides) and improvement in clinical symptoms (e.g., angina frequency and ECG results).
Search Strategy and Data Synthesis
A comprehensive search will be performed across seven major databases: PubMed, Embase, the Cochrane Library, and four specialized Chinese databases (CNKI, Wanfang, CBM, and VIP). Data synthesis will be performed using Review Manager 5.3. Categorical outcomes will be expressed as Risk Ratios (RR), while continuous outcomes will use Mean Difference (MD). A fixed-effect model will be employed unless significant heterogeneity (I² > 50%) is detected, in which case a random-effects model will be used.
Discussion and Expected Impact
This study represents a significant effort to bridge traditional Chinese medicine (TCM) with modern evidence-based pharmacology. By moving beyond anecdotal clinical use toward standardized statistical rigor, the researchers hope to establish SBP as a potent adjuvant that potentially allows for superior lipid control compared to statins alone.
A unique goal of this review is the quantification of an optimal SBP dosage. Herbal supplements often suffer from inconsistent dosing across different trials; establishing a standardized recommendation is a critical step for clinical translation and the refinement of integrated medicine guidelines in cardiology.
Limitations
The reliability of the meta-analysis depends on the quality of the primary RCTs. Potential limitations include clinical and methodological heterogeneity due to variations in statin types, treatment durations, and patient demographics. Furthermore, the risk of publication bias will be rigorously evaluated using funnel plot analyses.
Conclusion
Once finalized, the results of this systematic review will provide a foundation for evidence-based clinical practice. By clarifying the efficacy and safety profile of SBP-statin combination therapy, this work will inform future large-scale, multi-center trials and help optimize treatment strategies for patients with coronary heart disease.
Summary updated